| Biotechnology Industry | Healthcare Sector | Dr. Yongtai Hou Ph.D. CEO | SSE Exchange | CNE100003NX4 ISIN |
| DE Country | 2,156 Employees | 17 Jun 2026 Last Dividend | 20 Jun 2024 Last Split | - IPO Date |
Shanghai Haohai Biological Technology Co., Ltd., established in 2007 and headquartered in Shanghai, China, stands as a paramount figure in the biomedical materials industry, not only within its domestic borders but also internationally. The company initially known as Haohai Limited until its rebranding in 2010, has carved a niche for itself through its dedication to research, development, manufacture, and sale of a wide range of biomedical products. Engaging in a broad spectrum of sectors, including ophthalmology, medical aesthetics, biological engineering, and pharmaceutical products, Shanghai Haohai Biological Technology Co., Ltd. also extends its expertise to technology transfer and consultation services. This multifaceted approach underscores the company’s commitment to advancing healthcare through innovation.
Shanghai Haohai Biological Technology Co., Ltd.'s portfolio encompasses an extensive array of products and services designed to meet the diverse needs of the medical and healthcare communities: